NANTES, France, November 7, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotechnology company developing immunotherapies for cancer and autoimmune ...
As of Friday, November 07, CytomX Therapeutics, Inc.’s CTMX share price has dipped by 18.38%, which has investors questioning ...
Recently, new drugs - analogs of the gut hormone glucagon-like peptide-1 (GLP-1) have been added to the therapeutic arsenal, ...
Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; ...
Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE™ molecules in ...
Medpage Today on MSN
Novel Drug Led to Meaningful Weight Loss in Adults With Obesity
Subcutaneous injections of an investigational, selective long-acting amylin receptor agonist led to clinically meaningful ...
Celltrion announced on November 5 that it will present preclinical results for its multi-antibody new drug, CT-P72/ABP-102, at the SITC 2025 (Society ...
The results send a ‘clear, pragmatic message’ of IL-17 inhibition’s greater potency over IL-12/23 inhibition, an expert says.
Findings provide scientific insights into the contribution of small interfering RNA (siRNA) and therapeutic vaccination towards the HBV functional cure strategy DURHAM, N.C. and BEIJING, Nov. 7, 2025 ...
Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look ...
The FDA has approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for treating major depressive ...
Caplyta is now FDA-approved for MDD treatment in adults, marking its fourth indication, including bipolar I and II depression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback